Seyit Ali KAYIŞ, Fatma KAYA, Hüsamettin VATANSEV, Bülent ORAN, Derya ÇİMEN, Hasibe ARTAÇ, Derya ARSLAN

N-terminal-pro brain natriuretic peptide levels in children with allergic rhinitis

Background/aim: Persistent upper airway obstruction may lead to increased pulmonary arterial pressure (PAP). The aim of this study was to evaluate N-terminal pro brain natriuretic peptide (NT-proBNP) concentrations and PAP values in children with allergic rhinitis. Materials and methods: Sixty-six patients with allergic rhinitis and 22 healthy children were prospectively enrolled in this study. Plasma NT-proBNP levels were measured at first admission and after treatment. Simultaneously, echocardiography was done to assess pulmonary arterial hypertension, and rhinitis symptom scores were recorded. Results: The median age of the study group was 9.0 (5.0‒17.0) years; 26 were female. PAP was found to be normal in all the patients. There was a negative correlation between age and NT-proBNP levels (r = −0.452, P < 0.01). Nasal blockage levels affected NT-proBNP levels mildly (P = 0.067). No significant difference between before and after nasal steroid treatment was observed in NT-proBNP levels. Conclusion: These results suggest that NT-proBNP level and PAP may not be affected in children with allergic rhinitis, and primarily this influence may be associated with the severity of nasal obstruction.

PDF

___

1. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008; 122: S1-84.
2. Jáuregui I, Dávila I, Sastre J, Bartra J, del Cuvillo A, Ferrer M, Montoro J, Mullol J, Molina X, Valero A. Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: the PEDRIAL study. Pediatr Allergy Immunol 2011; 22: 388-392.
3. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richard AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1130.
4. Reisli I, Oran B, Baspınar O, Baysal T, Karaaslan TS. Pulmonary arterial pressure in children with allergic rhinitis. Am J Rhinol 2004; 18: 227-232.
5. Yüksel H, Coşkun S, Onağ A. Doppler echocardiographic evaluation of pulmonary arterial pressure in children with allergic rhinitis. Int J Pediatr Otorhinolaryngol 2001; 60: 21-27.
6. Bayrak P, Kirmaz C, Sekuri C, Yuksel H. Is pulmonary arterial pressure affected by allergic rhinitis with nasal obstruction? Asian Pac J Allergy Immunol 2007; 25: 121-126.
7. Nasser N, Perles Z, Rein AJ, Nir A. NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis. Pediatr Cardiol 2006; 27: 87- 90.
8. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease and the right heart. Chest 2004; 126: 1330-1336.
9. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, Kuribayashi S, Hamada S, Kakishita M, Nakanishi N et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31: 202-208.
10. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization GA(2)LEN and AllerGen). Allergy 2008; 86: 8-160.
11. GINA report: Global strategy for asthma management and prevention. Update December 2012. Available from: www. ginasthma.org.
12. Hanafin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatovener (Stockholm) 1980; 92: 44-47.
13. Feigenbaum H. Echocardiography. 5th ed. Lea & Febiger, Philadelphia, PA, USA: 1994, pp. 181-215.
14. Li WZ, Du JB, Ma YW, Li YA, Li XM. Pulmonary arterial pressure evaluated by pulsed Doppler echocardiography in children with a left-to-right intracardiac shunt. Pediatr Cardiol 1991; 12: 17-19.
15. Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. Eur Respir J 2003; 21: 155-176.
16. Minitab, Inc. 2003. MINITAB 14 statistical software. Minitab Inc., State College, PA, USA.
17. Goldbart AD, Levitas A, Greenberg-Dotan S, Ben Shimol S, Broides A, Puterman M, Tal A. B-type natriuretic peptide and cardiovascular function in young children with obstructive sleep apnea. Chest 2010; 138: 528-535.
18. Oran B, Ozturk K, Cimen D, Vatansev H, Bulut S, Arslan D. Release of NT-pro brain natriuretic peptide in children before and after adenotonsillectomy. Int J Pediatr Otorhinolaryngol 2013; 77: 666-669.
19. Naiboglu B, Deveci S, Duman D, Kaya KS, Toros S, Kinis V, Sürmeli M, Deveci I, Gokceer T. Effect of upper airway obstruction on pulmonary arterial pressure in children. Int J Pediatr Otorhinolaryngol 2008; 72: 1425-1429.
20. Van Albada ME, Loot FG, Fokkema R, Roofthooft MT, Berger RM. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res 2008; 63: 321- 327.
21. Abdel-Aziz M. Asymptomatic cardiopulmonary changes caused by adenoid hypertrophy. J Craniofac Surg 2011; 22: 1401-1403.